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Abstract
Objective: To evaluate the diagnostic performance of two rapid detection tests (RDTs) for HIV 1/2 in plasma and in whole
blood samples.
Methods: More than 15,000 study subjects above the age of two years participated in two rounds of a cohort study to
determine the prevalence of HIV. HIV testing was performed using the Determine HIV 1/2 test (Abbott) in the first (2006/
2007) and the HIV 1/2 STAT-PAK Dipstick Assay (Chembio) in the second round (2007/2008) of the survey. Positive results
were classified into faint and strong bands depending on the visual appearance of the test strip and confirmed by ELISA and
Western blot.
Results: The sensitivity and specificity of the Determine RDT were 100% (95% confidence interval = 86.8 to 100%) and
96.8% (95.9 to 97.6%) in whole blood and 100% (99.7 to 100%) and 97.9% (97.6 to 98.1%) in plasma respectively. Specificity
was highly dependent on the tested sample type: when using whole blood, 67.1% of positive results were false positive, as
opposed to 17.4% in plasma. Test strips with only faint positive bands were more often false positive than strips showing
strong bands and were more common in whole blood than in plasma. Evaluation of the STAT-PAK RDT in plasma during the
second year resulted in a sensitivity of 99.7% (99.1 to 99.9%) and a specificity of 99.3% (99.1 to 99.4%) with 6.9% of the
positive results being false.
Conclusions: Our study shows that the Determine HIV 1/2 strip test with its high sensitivity is an excellent tool to screen for
HIV infection, but that – at least in our setting – it can not be recommended as a confirmatory test in VCT campaigns where
whole blood is used.
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Introduction
The World Health Organisation (WHO) Global Programme on
AIDS first recommended the use of simple rapid detection tests
(RDTs) for HIV in 1992 [1]. Since then RDTs have been widely
used throughout Africa and the developing world for blood safety
screening, surveillance and in prenatal or voluntary counselling
and testing (VCT) centres [2]. Until recently the National
guidelines for VCT in Tanzania recommended using the SD
Bioline HIV 1/2 3.0 (Standard Diagnostics, Kyonggi-do, Korea)
as a screening test, with initial reactive samples re-tested using the
Determine HIV 1/2 test (Abbott Laboratories, Abbott Park, IL).
The Uni-GoldTM HIV-1/2 (Trinity Biotech, Bray Ireland) is used
as a final test if results are discrepant [3]. A fourth HIV rapid test,
HIV 1/2 STAT-PAK (Chembio Diagnostics Systems, Medford,
NY, USA) is used in neighbouring countries mainly as a
confirmatory test. All four RDTs are less expensive than ELISA
or Western Blot tests, require little or no equipment, can be stored
at room temperature and are easy to use and to read. Because they
allow for real-time, point-of-care HIV testing, individuals can
receive their test result during a single clinic visit which is likely to
increase the uptake of VCT [4,5], especially in Sub Saharan
Africa, where in some settings more than two weeks may be
needed for laboratory results to become available [6]. However, it
seems that the diagnosis of HIV by RDT is challenged by
confounding regional factors. Especially the Determine HIV 1/2
test received very diverse reports regarding its specificity which
ranged from 91.7% to above 99% [7,8,9,10,11,12].
Here we evaluate the diagnostic test performance for HIV
testing of the Determine HIV 1/2 and the HIV 1/2 STAT-PAK
(Chembio Diagnostics Systems, Medford, NY, USA) RDTs in a
general population cohort in South West Tanzania where, in
contrast to previous studies, children and adults of both genders
were included. The two tests are referred to below as the
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39529
‘‘Determine’’ RDT and the ‘‘STAT-PAK’’ RDT, in order to
improve the readability of this article. The manufacturer’s
information applies to the time of the study; today both tests are
manufactured and sold by Alere, formerly named Inverness
Medical Professional Diagnostics, Princeton, NJ.
Methods
Ethical Considerations
The study was approved by the National Ethical Committee/
Medical Research Coordinating Committee of the National
Institute for Medical Research, Tanzania. All adult participants
provided written informed consent prior to enrolment into the
study. Parents gave the permission for their children, if they were
below 18 years of age. In addition children above the age of 12
years signed their own consent form together with their parents.
The study, including the consent forms for adults and children,
was additionally approved by the Mbeya Medical Research and
Ethics Committee.
Data Collection
Data for this study were collected between May 2006 and June
2008 in the Mbeya Region in Tanzania. The EMINI project
(Establishment of the infrastructure to Evaluate and Monitor the
Impact of New Interventions), a population based cohort study,
investigated the prevalence and incidence of HIV in 9 selected
communities with a total population of ,171,000 people. The
urban, semi-urban and rural study sites were carefully chosen in
order to reflect the geographic diversity of the Region, from
altitudes of about 475 meters above sea level near Lake Nyassa, to
over 2300 meters. Subsequently, 10% of all households in the
study sites were randomly selected, which resulted in a cohort of
approximately 18,000 individuals of all age groups and both sexes.
Study participants were visited annually for specimen and data
collection, including an HIV rapid test. Collected data further
included socio-economic characteristics of the study participants,
previous and current medical history, as well as individual
knowledge regarding different diseases.
During the first survey (2006/2007) the Determine RDT was
used to screen for HIV-1 infection. 2.7 ml of blood were collected
by venae puncture from participants above the age of 6 years.
However, venae puncture was not possible in all participants, and
especially problematic in younger children. In these cases, 300 ml
of blood were collected after finger prick, using microvettes
(Sarstedt, Nu¨rnbrecht, Germany). In most cases this smaller
amount of blood did not supply sufficient plasma, so that HIV
testing in children below 6 years was mostly done using whole
blood. During the second and third annual survey round, where
the STAT-PAK RDT was used for HIV screening, we collected
2.7 ml of blood from all participants above 2 years of age, thus all
our STAT-PAK RDT results were obtained from plasma samples.
Results of the third survey are not reported here, they were only
used when needed to verify results from the two previous surveys.
For both RDTs our results only include data from participants
above the age of 2 years in order to exclude false test-positivity due
to the presence of maternal antibodies.
According to the manufacturer’s instructions for both assays,
any test result with visible lines in both test control areas,
regardless of intensity, were considered reactive [13,14]. How-
ever, we recorded variations of intensity of the strip test. Any
assay with an apparent positive band which was noticeably
lighter than the control band on the test card was regarded as
‘‘faint’’.
Additional testing to verify the initial RDT results was only done
if.
i. the RDT result was the first HIV positive result obtained from
this participant (true for positive results from survey 1 and
newly positive results from survey 2), or if
ii. the RDT result differed from the result of the previous or the
following survey.
In these cases the sample was retested using an ELISA HIV test
(Enzygnost Anti HIV 1/2 Plus, DADE-Behring, Marburg,
Germany) (Figures 1 and 2). Samples where the RDT and the
ELISA had discordant results were tested again, using a second
ELISA (rLAV, Biorad Laboratories, Redmond WA, USA). If both
ELISAs were in agreement, the ELISA result was used as the
reference-standard. Samples with discordant ELISA results were
retested byWestern Blot (MPDHIV Blot 2.2, MP Biomedicals, and
Geneva, Switzerland) to determine the HIV status. If the Western
Blot result was indeterminate, the results for this sample were
excluded from statistical analysis. In addition, samples with
discordant results were repeat-tested with the respective RDT to
reconfirm the initial RDT results and to exclude a technical error.
Retesting of whole blood results was not possible due to lack of
stored plasma. Insteadwe regarded these results as true positive if the
result in the next survey was also positive and as false positive if the
participant had a negative test result in the subsequent survey, which
was confirmed using the above reference algorithm. Whole blood
results from participants not participating in at least one of the two
following surveys were excluded from our analysis because their true
HIV status could not be determined.
Negative RDTs from the first or second annual surveys which
were confirmed by another negative RDT in the following survey
and were not in conflict with earlier positive results, were regarded
as confirmed and not further tested. For all HIV incident cases,
which were found newly positive in surveys 2 or 3, the negative
result of the previous round was confirmed by the above described
testing reference algorithm.
All participants from the nine different study sites were visited at
their home. The collected specimens were brought to the central
laboratory in Mbeya, where the RDTs were performed in order to
ascertain comparable test quality across sites and field teams. In
addition to HIV other concomitant infections and influences were
examined. Plasmodium falciparum infection was assessed using Rapid
Malaria Tests (ICT Diagnostics, Cape Town, South Africa) and
Schistosoma haematobium infection was assessed by urine microscopy
for S. haematobium eggs.
Information on elevationwas retrieved using data from theNASA
Shuttle Radar TopographyMission (SRTM) global digital elevation
model (DEM) version 2.1 with a nominal resolution of 90 meters.
Annual ambient temperature interpolated surfaceswith 1 km spatial
resolution were downloaded from theWorldClim – Global Climate
Data website (http://www.worldclim.org/) [15,16]. These data and
the participant household’s positions which had been collected using
handheldGPS receiverswere combined in a geographic information
system in order to calculate elevation and mean annual ambient
temperature at the household position.
Statistical Analysis
All statistical analyses were performed using Stata version 10
(Stata Corp., College Station, TX). Diagnostic test performance
(sensitivity, specificity, predictive values and diagnostic likelihood
ratios) was calculated only for participants where a definitive HIV
diagnosis (reference-standard) was available, using the ‘‘diagt’’
Stata component. Because predictive values are affected by the
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prevalence of disease in the tested population, we also report the
positive and negative diagnostic likelihood ratios (DLRs), which
are less affected by prevalence [17]. DLRs incorporate both the
sensitivity and specificity of a test and provide a direct estimate of
how much a test result will change the odds of having or not
having a disease. DLR calculation uses the following formulae:
positive DLR~sensitivity= 1{specificityð Þ
negative DLR~ 1{sensitivityð Þ=specificity:
Positive DLRs can thus range from unity to infinity, negative
DLRs from unity to 0 with better tests having DLRs further away
from unity.
Uni-variable and multi-variable binomial regression with a log
link adjusted for within household clustering was used to calculate
risk ratios for possible associations of false positive RDT results
with participant age, sex, P. falciparum and S. haematobium infection
status, and elevation and annual mean ambient temperature at the
participant’s residence.
Results
During the first survey we obtained Determine RDT results
from 8,747 female and 7,590 male participants between 2 and
97 years of age with a median age of 19.8 years (inter-quartile-
range [IQR] =10.2 to 35.3) and 16.8 years (IQR =9.2 to
34.1) respectively. Of these RDT results 1,889 were obtained
using whole blood samples (median age = 4.1 years, range 2 to
87, IQR =2.9 to 5.3 years) and 14,448 using plasma (median
age = 21.1 years, range 2 to 97, IQR =12.1 to 36.9). Samples
that could not be verified according to the above reference
algorithm were excluded. Therefore, the below analysis was
done with 1,696 and 12,916 Determine RDT results, obtained
from testing whole blood and plasma samples respectively
(Figure 1).
During the second survey the STAT-PAK RDT was used
instead of the Determine RDT and we collected 2.7 ml of blood
by venae puncture from all participants above the age of 2 years,
so that testing with whole blood was no longer necessary. We
obtained STAT-PAK RDT results from 8,574 female and 7,383
male participants with a median age of 19.1 (range = 2 to 98,
IQR =9.9 to 35.6) and 16.1 (range = 2 to 96, IQR =8.8 to 34.0)
Figure 1. HIV-Testing Algorithm and Exclusion criteria Survey 1. In Survey 1 we tested 1,889 whole blood specimen and 14,448 plasma
specimen with the Determine HIV1/2 RDT. The confirmation algorithm included two different ELISAs and one Western Blot. If both ELISAs were in
agreement their result was used as the reference standard result. Samples with discordant ELISA results were retested by Western Blot and the
Western Blot result used. Samples with indeterminate Western Blot results were excluded from analysis. Negative RDT results were not directly
confirmed, but regarded as true negative if the result of the following survey was also negative. Whole blood results where confirmation by ELISA
testing was impossible due to lack of plasma, were regarded as true positive if the result in the next survey was confirmed positive and as false
positive if a negative test result in the next survey was confirmed using the above reference algorithm. Results where the true HIV status could not be
verified according to the reference algorithm were excluded from this analysis.
doi:10.1371/journal.pone.0039529.g001
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years respectively. Again we excluded all samples where verifica-
tion of the result was not possible which resulted in performing the
analysis with 13,139 STAT-PAK RDT results, all derived from
plasma samples (Figure 2).
Determine RDT
The sensitivity and specificity of the Determine RDTwere 100%
and 96.8% in whole blood and 100% and 97.9% in plasma
respectively. We did not encounter any false negative results with
this test (tables 1 and 2). However, the positive predictive value was
low inplasma (82.6%) andvery low inwhole blood (32.9%),meaning
that 67.1% of the positive results were incorrect in whole blood and
17.4% in plasma. This high proportion of false positive tests was
mainly due to the appearanceof faint bands.Only2%ofwholeblood
samples with faint bands were truly HIV-1 positive according to the
reference-standard. In plasma the proportion of true positive faint
bands was 7.6%. For those whole blood and plasma samples where
strong bands were recorded the concordance with the reference-
standard was 86.2% and 96.4% respectively.
STAT-PAK RDT
The sensitivity and specificity of the STAT-PAK RDT were
99.7% and 99.3% respectively; the positive and negative predictive
values were 93.1% and 99.97%. Of the 11,886 samples with a
negative STAT-PAK RDT result, four were positive according to
ELISA and Western Blot testing. All four tests had a positive result
in the previous and the following survey but were repeatedly
negative when retested using the STAT-PAK RDT. Of the 1,253
positive STAT-PAK RDT results 9.7% showed a faint band, and
again the proportion of true positives was lower in faint-banded
(45.5%) than in strong-banded tests (98.1%). Of the positive RDT
results, 1166 (93.1%) were confirmed with the reference algorithm.
Figure 2. HIV-Testing Algorithm and Exclusion criteria Survey 2. In Survey 2 we tested only plasma samples from 15,957 participants
using the STAT-PAK-HIV1/2 RDT. The confirmation algorithm was essentially the same as in Survey 1.It included two different ELISAs and one
Western Blot for RDT positive samples. Participants, who’s positive RDT result had been confirmed in Survey 1 already were not re-tested. 319
negative RDT results were directly confirmed by Behring ELISA, 11563 were regarded as true negative because the result of the following survey
was also negative.
doi:10.1371/journal.pone.0039529.g002
Table 1. Diagnostic Test performance of Determine and
STAT-PAK RDT numbers of positive and negative results.
HIV RDT: Determine STAT-PAK
tested sample: whole blood plasma plasma
N included 1696 12916 13139
Reference standard positives 26 1184 1170
Reference standard negatives 1670 11732 11969
True positives, all 26 1184 1166
True positives, faint bands 1 17 55
True positives, strong band 25 1167 1111
False positives, all 53 250 87
False positives, faint band 49 207 66
False positives, strong band 4 43 21
True negatives 1617 11482 11882
False negatives 0 0 4
doi:10.1371/journal.pone.0039529.t001
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Comparison of Determine and STAT-PAK Performance
The 250 false positive plasma samples from survey 1 were
retested with the Determine RDT in order to exclude technical
errors. The Determine RDT was repeatedly false positive in all
samples. To compare the performance of the two RDTs in false
positive samples, we later re-tested 25 (10%) of these false positive
plasma samples from survey 1 with the STAT-PAK RDT. None
of these samples was positive using the STAT-PAK RDT. The
250 participants with false positive plasma samples in Survey 1
were followed closely in the consecutive surveys. Thirty-six did not
join the surveillance in survey 2, of the remaining 214 participants
only 2 had a false positive test result again using the STAT-PAK
RDT. However, in other survey 2 participants the STAT PAK
RDT was actually false positive, demonstrating a different pattern
of false positivity for both tests. In order to investigate whether
false-positivity might be a transient problem or a feature associated
with the Determine RDT, samples of 19 participants who had a
false positive result in survey 1 were re-tested in survey 2 both with
the STAT PAK and the Determine RDT. It appeared that the
false positive result of the Determine RDT was not transient, but
persisted in 10 out of 19 cases (52.6%) whereas STAT-PAK RDTs
performed on the same samples were negative in all these cases.
Comparing the Determine RDT results which were obtained in
plasma, with those of the STAT-PAK RDT, we found a higher
positive predictive value and a higher specificity of the STAT-
PAK RDT. Four false negative results however lead to a lower
sensitivity of the latter test. Comparing the overall performance of
both tests we found a positive DLR of 46.9 for the Determine
RDT and of 137.1 for the STAT-PAK RDT, when using plasma
for both tests. This means that in our study population the initial
likelihood to be HIV-infected increases 46.9 times with a positive
Determine RDT and 137.1 times after receiving a positive result
with the STAT-PAK RDT when these tests are done with plasma
samples.
Possible Influence of Concomitant Infections
We hypothesized that false positive results for both RDTs might
be related to exposure to infectious agents other than HIV.
Therefore we examined the associations of co-infection with S.
haematobium (urinary schistosomiasis) and P. falciparum (malaria
tropica), participant age, sex, altitude and ambient temperature at
the site of the participant’s home with false positivity (coded as 0=
RDT true negative; 1 = RDT false positive) as the binary
outcome, using only results obtained in plasma samples. The
binomial regression models (tables 3 and 4) showed significant
associations of false-positivity with age, both for the Determine
RDT (probability ratio (PR) per 10 years increase in age = 1.09;
95% confidence interval (95%CI) = 1.03 to 1.15) and for the
STAT-PAK RDT (PR =1.10; 95%CI = 1.00 to 1.21), indicating
that the probability of a false positive result in both tests increases
by about 10% with a 10 years increase in age. Furthermore, false
positive results of the Determine RDT were associated with low
altitude (PR per 100 m increase = 0.78; 95%CI = 0.66 to 0.93).
Associations of Determine RDT false positivity with ambient
temperature and P. falciparum co-infection, which were significant
in uni-variable regression, both became non-significant in the
multi-variable analysis when altitude of residence was included
into the model.
As opposed to the Determine RDT, false positive STAT PAK
results were also associated with participant sex, with males having
a significantly lower proportion of false positive results than
females (PR = 0.63, 95%CI = 0.42 to 0.98).
Discussion
An essential requirement of all HIV testing is the accuracy of
the test results. HIV RDTs are usually designed to be used as
screening tests with a positive result being confirmed by more
specific methods. Therefore they are geared towards high
sensitivity. This is reflected in the results of both RDTs that we
evaluated: when read according to manufacturer’s instructions, the
Determine RDT was 100% sensitive and the sensitivity of the
STAT-PAK RDT was very close to this optimum. However, both
tests had problems regarding specificity, which – for the
Determine RDT – was worse when using whole blood instead
of plasma for testing.
According to a WHO publication from 2002, the sensitivity and
specificity of the Determine RDT in whole blood was 100% and
99.7% respectively [18]. Studies from the Ivory Coast [10], the
Central African Republic [11], Cameroon [19], Tanzania [20,21]
and the Netherlands [12] reported slightly lower sensitivities, but
similar specificity when using plasma [10,11,12] or whole blood
[19,20,21]. However, two recent publications from Uganda
demonstrated lower than expected specificities of 94% [7] and
91.7% [8] for the Determine RDT.
Table 2. Diagnostic Test performance of Determine and STAT-PAK RDT sensitivity, specificity, predictive values and likelihood
ratios.
Determine RDT in whole blood Determine RDT in blood plasma STAT-PAK RDT in blood plasma
Result 95%CI Result 95%CI Result 95%CI
HIV prevalence according to reference
standarda (%)
1.53 1.00 to 2.24 9.17 8.67 to 9.68 8.90 8.42 to 9.40
Sensitivity (%) 100.00 86.77 to 100.00 100.00 99.69 to 100.00 99.66 99.13 to 99.91
Specificity (%) 96.83 95.87 to 97.61 97.87 97.59 to 98.12 99.27 99.10 to 99.42
Positive predictive value (%) 32.91 22.75 to 44.40 82.57 80.50 to 84.50 93.06 91.51 to 94.40
Negative predictive value (%) 100.00 99.77 to 100.00 100.00 99.97 to 100.00 99.97 99.91 to 99.99
ROC area 0.984 0.980 to 0.988 0.989 0.988 to 0.991 0.995 0.993 to 0.996
Positive likelihood ratio 31.51 24.18 to 41.07 46.93 41.51 to 53.05 137.10 111.20 to 169.04
Negative likelihood ratiob 0.00 – to – 0.00 – to – ,0.01 0.00 to 0.01
aPrevalences differ from total population prevalence due to exclusion of participants.
bNo confidence interval can be calculated if sensitivity = 100%.
doi:10.1371/journal.pone.0039529.t002
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One possible reason for these diverse reports could be the
subjective interpretation of test results [22]. A recent study from
Uganda suggests that the difference in reported specificity of the
Determine RDT could be caused by different interpretation of
faint positive bands [7]. The authors found a specificity of 94.1%
for the Determine RDT in plasma, which improved to 99.6% after
exclusion of faint positive bands. Our data confirm these findings
in a much larger population and show that the problem is
aggravated when using whole blood instead of plasma. The
interpretation of faint positive bands as negative might thus be one
reason for the differences in sensitivity and specificity of the
Determine RDT that are reported in some of the previous studies.
Most studies that examine the diagnostic performance of HIV
RDTs use plasma or serum for testing. However, another study
from Uganda that used whole blood found a specificity of the
Determine RDT of only 96.2% which is very similar to our results
[23].
Because the STAT-PAK RDT results were exclusively derived
from plasma samples we can only compare them to the plasma
results of the Determine RDT. The STAT-PAK RDT was
considerably more specific than the Determine RDT. However,
still 6.9% of all positive test results were false and again the
proportion of true positives was lower in faint-banded (45.5%)
than in strong-banded tests (98.1%).
It is noteworthy that half of our participants with false positive
Determine RDT results were still false positive when re-tested with
the Determine RDT one year later. This shows that for these
participants the cause of the false positive result remains present
over at least 12 month. It has been suggested that the laboratory
diagnosis of HIV might be confounded by regional factors, for
example cross reaction with antibodies against other diseases such
as schistosomiasis [24]. We demonstrated that in our study area
with an altitude range from 475 to over 2300 meters, false positive
results of the Determine RDT, but not the STAT-PAK RDT, are
more common in the lower parts with higher ambient tempera-
tures that favour co-infections with various infective agents
[25,26]. In contrast to the published data regarding the Murex
HIV Ag/Ab Combination EIA [24] we did not find an association
with concurrent schistosomiasis infection for any of the rapid tests.
Results in the uni-variable analyses show an association of
Determine RDT false positivity with P. falciparum infection with
nearly twice as many false positive Determine results in
participants who were co-infected with P. falciparum. However, in
multi-variable analysis, which included altitude of residence as an
independent variable, this association became non-significant,
suggesting that the cause of the false positive result was not P.
falciparum infection. Similarly ambient temperature became non-
significant when adjusted for altitude. It might be that in low
altitude regions of our study area, where several other infections
are common [27], humoral immune responses against concom-
itant infections interfere with the Determine RDT result. These
potential cross-reactions could explain some of the differences
between previous reports regarding the diagnostic performance of
the Determine and other RDTs.
Interestingly we found no such association for temperature,
altitude or co-infection with P. falciparum for the Stat-Pak RDT
false positivity. The gender difference showing less false positive
STAT PAK results in men than in women was not reported
previously. This might be due to the fact that most studies focus on
either women (microbicide trials) or men (circumcision trials). But
we presently do not have an explanation for this finding.
Table 3. Association of various factors with false positive
Determine RDT results in plasma; uni- and multi-variable log-
link binomial regression results adjusted for clustering within
household (N= 11732).
uni-variable multi-variable*
Covariate
stratum PR 95%CI P PR 95%CI P
Age
per 10 years 1.10 (1.04 to 1.16) 0.001 1.09 (1.03 to 1.15) 0.002
Elevation
per 100 meters 0.88 (0.86 to 0.90) ,0.001 0.78 (0.66 to 0.93) 0.006
Ambient temperature
per oC 1.26 (1.20 to 1.32) ,0.001 0.81 (0.59 to 1.10) 0.180
P. falciparum infection
negative 1 - - 1 - -
positive 1.93 (1.07 to 3.47) 0.028 1.47 (0.81 to 2.68) 0.210
Gender
female 1 - -
male 1.00 (0.79 to 1.27) 0.992
S. haematobium infection
negative 1 - -
positive 0.99 (0.58 to 1.69) 0.980
PR = probability ratio for a false positive result; p = p-value; 95% CI = 95%
confidence interval.
*covariates were only included in multi-variable model if uni-variable p-value
,0.2.
doi:10.1371/journal.pone.0039529.t003
Table 4. Association of various factors with false positive
STAT-PAK RDT results in plasma; uni- and multi-variable log-
link binomial regression results adjusted for clustering within
household (N= 11969).
uni-variable multi-variable*
Covariate
stratum PR 95%CI P PR 95%CI p
Age
per 10 years 1.11 (1.01 to 1.21) 0.035 1.10 (1.00 to 1.21) 0.045
Gender
female 1 - - 1 - -
male 0.63 (0.41 to 0.96) 0.031 0.64 (0.42 to 0.98) 0.038
Elevation
per 100 meters 1.02 (0.97 to 1.06) 0.444
Ambient temperature
per oC 0.99 (0.92 to 1.07) 0.808
S. haematobium infection
negative 1 - -
positive 0.62 (0.15 to 2.52) 0.502
PR = probability ratio for a false positive result; p = p-value; 95% CI = 95%
confidence interval.
P. falciparum infection not included due to empty cells (no false positive results
in P. falciparum infected participants because of low P. falciparum prevalence in
survey 2).
*variables were only retained in multi-variable model if uni-variable p-value
,0.2.
doi:10.1371/journal.pone.0039529.t004
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Since age is a proxy for lifetime exposure to different diseases,
cross reactions with persisting antibodies to other diseases should
occur more frequently in older people, which is compatible with
the rise of false positivity with age which is apparent in our data.
The relatively high number of false positive results that we
found for both tests may not be a problem in settings where every
positive screening result is confirmed by more specific, reliable and
expensive methods. It is however problematic in resource
constrained VCT settings, where testing is done on whole blood
and where positive RDT screening results are usually confirmed
only by additional RDTs, which might be susceptible to the same
characteristics that caused the initial false positive result.
Since most of our false positive results showed faint bands, it is
an important question how to deal with these. Interpreting them as
negative is problematic as it would decrease sensitivity (e.g. from
100% to 98.6% for Determine RDT testing of plasma in our
study) and classify some HIV-infected patients as uninfected with
all the negative consequences this would have for transmission and
the management of their infection. Interpreting them as positive
would also be problematic as it would further decrease specificity
of the test and cause unnecessary anxiety in some patients. We
therefore believe that the best option in a screening setting is to
record the strength of the band when testing and to consider this
information once the standard testing reference algorithm for a
positive sample is finalised. Positive results with faint bands should
therefore be considered for additional testing in one of the Care
and Treatment Centres, which have access to more specific
methods, such as ELISA, Western Blot or PCR testing.
To avoid too many questionable results it would be best to chose
a testing strategy which leaves as few open questions as possible.
Thus it seems more sensible to use the Determine RDT with its
high sensitivity but low specificity during initial screening and not
as a confirmatory test as it was practiced until recently. For
confirmation, a more specific test such as the Stat-Pak RDT
should be used.
A strength of this study is its huge sample size and the fact that it
includes male and female participants of all age groups, apart from
infants. To our knowledge it is the first study to date to confirm the
findings from Uganda showing that faint bands pose a problem
when using the Determine RDT with plasma [7]. It is the only
study which shows that this problem also occurs when using the
STAT-PAK RDT and is aggravated when using whole blood. The
two main limitations of this study concern the lack of direct
confirmation (i.e. retesting of the same sample by other means) of
negative results in whole blood and in plasma and of positive
results obtained with whole blood. As mentioned above, RDT-
negative samples were only retested if the RDT-result of the
previous or the next survey was in disagreement ( = positive) and
regarded as reference-standard-negative if the result in the
following survey was also negative. This could have led us to
overestimate the sensitivity of both tests because we can not
exclude that both the Determine and the STAT-PAK RDT are
repeatedly false-negative in the same person. However, we believe
that this would occur only very rarely, if at all. This is supported by
the fact that none of the Determine-negative plasma samples that
needed to be retested due to a positive RDT result in the next
survey were regarded as positive according to our testing reference
algorithm.
Because retesting of positive Determine RDT results obtained
from whole blood samples was impossible due to lack of plasma,
these were regarded as true positive if the result of the following
survey was confirmed positive, as false positive if the result of the
following survey was confirmed negative and excluded from this
analysis if no HIV results from later surveys were available. This
could have increased our specificity estimates for the Determine
RDT in whole blood if initially HIV negative participants with a
false positive Determine RDT result got HIV infected before the
following survey. Equally it could have decreased our specificity
estimates if an initial positive Determine RDT result was due to
technical error. Although both is possible, it is again unlikely that
this has happened in more than a few cases which would only
marginally change the numbers presented here. Furthermore the
specificity of the Determine RDT in whole blood is so low that a
slight change in this diagnostic parameter would not make any
difference in practice.
To summarize the above: Due to small shortcomings in our
reference standard we can not completely exclude that the true
sensitivities for both tests are slightly lower than reported in this
article and that the true specificity of the Determine in whole
blood may slightly deviate from the result reported here. However,
both is unlikely, and with the large number of tests that were done,
the very few cases where the reference standard might be incorrect
would not substantially change the presented results.
Conclusion
The Determine RDT strip test can not be recommended as a
confirmatory test for prevalence studies and in VCT settings, due
to its low specificity and low positive predictive value. The
specificity of the test is even lower when using whole blood instead
of plasma. However, with its optimal sensitivity of 100%, the
Determine RDT is an excellent screening test, if another more
specific RDT is used for confirmation of positive test results. Since
our study did not apply the HIV-testing algorithm as stipulated in
the National guidelines for voluntary counselling and testing in
Tanzania, we are unable to judge the diagnostic performance of
this algorithm. Nevertheless, the practice of using the Determine
RDT as confirmatory assay in voluntary counselling and testing
settings, where whole blood is used, should be reconsidered. The
HIV 1/2 STAT-PAK RDT performed much better regarding
specificity and was only slightly less sensitive. However, the
problem of faint positive bands with their low positive predictive
value could also be demonstrated for the STAT-PAK RDT,
although to a far lesser extent.
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